Share this post on:

Product Name :
Nivolumab/Relatlimab

Search keywords :
Relatlimab

drugId :
null

Target Vo:
Lymphocyte activation gene 3 protein

Target Vo Short Name :
LAG3

Moa_Name:
Programmed cell death protein 1 blockers

First Approval Country :
United States

First Approval Date Filter:
2022

Origin Company_Name :
Bristol-Myers Squibb Company

Active Company_Name :
Bristol-Myers Squibb (China) Investment Co Ltd

Active Indication_Name:
Melanoma

In Active Indication_Name:
Colorectal Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
BTK Antibody (YA816)
AIF Antibody (YA835)
SREBP1 Antibody: SREBP1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 122 kDa, targeting to SREBP1. It can be used for WB,ELISA assays with tag free, in the background of Human, Mouse, Rat.

Share this post on:

Author: Interleukin Related